Compare Mechanisms, Dosing and Practical Differences
Understanding Prescription Weight Loss: Mounjaro or Wegovy Mechanisms
When considering Mounjaro or Wegovy for weight loss, understanding their different mechanisms is crucial for making an informed choice. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, helping reduce appetite and promote satiety after smaller meals. Mounjaro contains tirzepatide, a dual-action treatment targeting both GIP and GLP-1 receptors, offering a broader hormonal approach to appetite regulation. Both prescription-only medicines work alongside a reduced-calorie diet and increased physical activity to support sustainable weight management.
The practical implications of these different mechanisms become apparent during treatment. Wegovy's single-pathway approach through GLP-1 receptors has extensive clinical evidence from the STEP trial programme, whilst Mounjaro's dual-receptor targeting represents a newer approach with distinct dosing requirements. Both treatments require dose escalation over several months, but their titration schedules differ significantly. Your prescriber at EverydayMeds can assess which mechanism aligns better with your medical history and weight management goals during the clinical consultation process.
Pricing Comparison: Mounjaro or Wegovy for Weight Loss Costs
Understanding the cost implications when choosing Mounjaro or Wegovy for weight loss helps inform your treatment decision. Wegovy pricing at EverydayMeds starts with 0.25mg pens at £79.99 (with code FIRST40 for new customers), escalating to 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and maintenance 2.4mg at £209.99. Our Getting Started bundles provide convenient multi-pen supplies, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, ensuring seamless dose progression. Returning customers benefit from code DOSE25 applied at checkout for continued savings.
Both Mounjaro and Wegovy require similar financial commitment over the dose escalation period, but storage advantages may influence long-term costs. Wegovy's 6-week room temperature stability compared to Mounjaro's 21-day limit reduces waste risk during travel or temporary storage issues. Our 3-pen bundles like the Ultimate Stability Trio provide three months of maintenance supply for £649.99, offering convenience and Confirmed Availability. The clinical assessment fee remains consistent regardless of which treatment is most suitable, ensuring transparent pricing throughout your weight management journey.
Clinical Evidence: Comparing Mounjaro or Wegovy Weight Loss Data
The clinical evidence supporting both treatments when considering Mounjaro or Wegovy for weight loss comes from separate trial programmes with different methodologies. In the STEP trials, patients taking Wegovy alongside diet and exercise achieved an average of approximately clinically studied weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP programme included over 4,500 participants across multiple studies, establishing comprehensive safety and efficacy data.
Mounjaro's clinical evidence derives from the SURMOUNT trial series, which demonstrated significant weight management outcomes using different study designs and participant populations. Both treatments require ongoing commitment, as the STEP 1 extension study showed patients regained approximately two-thirds of lost weight within one year of stopping treatment. This emphasises that prescription weight loss with either option represents a long-term health management strategy rather than a short-term intervention.
How Wegovy Works: GLP-1 Mechanism for Weight Management
When evaluating Mounjaro or Wegovy for weight loss, understanding Wegovy's specific mechanism helps clarify its role in your treatment plan. Wegovy contains semaglutide, which binds to GLP-1 receptors in your brain's appetite control centres, mimicking the action of naturally occurring incretin hormones. This binding reduces hunger signals and enhances feelings of fullness after eating smaller portions, supporting calorie reduction without the constant battle against appetite. The once-weekly injection provides sustained hormone activity, maintaining appetite suppression between doses whilst allowing your body to adapt gradually during dose escalation. GLP-1 receptor activation also slows gastric emptying, contributing to prolonged satiety and reduced food cravings throughout the day.
Ordering Process: Getting Your Mounjaro or Wegovy Prescription
Starting your weight management journey with either option through EverydayMeds involves a streamlined process designed for convenience and clinical safety. The initial 3-minute online clinical assessment evaluates your medical history, current medications, and weight management goals to determine suitability for prescription weight loss treatment. Our prescribers review applications within 3 working days (or 24 hours with express service), ensuring thorough clinical oversight whilst maintaining efficient service delivery. Once approved, your chosen treatment ships via next-day delivery using cold-chain transportation to maintain medication stability. The process remains identical whether you're prescribed Wegovy or Mounjaro, with ongoing clinical support available throughout your treatment journey.
Storage and Practical Differences: Mounjaro or Wegovy Convenience
Practical storage considerations significantly impact daily life when choosing Mounjaro or Wegovy for weight loss, particularly for frequent travelers or those with busy lifestyles. Wegovy maintains stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit, offering greater flexibility for travel or temporary storage situations. Both treatments utilise pre-filled injection pens with straightforward administration, but their dose escalation schedules differ in timing and increments. The FlexTouch pen system used by Wegovy provides clear dose selection and injection feedback, whilst both treatments require refrigeration at 2-8°C for long-term storage. Weekly injection schedules for both options support treatment adherence, though the specific day can be adjusted within your routine as needed.
Personalised Treatment Selection: Which Suits Your Lifestyle?
Choosing between Mounjaro or Wegovy for weight loss involves matching treatment characteristics to your individual circumstances and preferences. Wegovy's established clinical pathway and longer room temperature stability suit patients who travel frequently or prefer treatments with extensive long-term data. The dose escalation schedule spans 16 weeks to reach maintenance dosing, allowing gradual adaptation to appetite changes and potential side effects.
Mounjaro's dual-receptor approach may appeal to patients seeking newer treatment mechanisms, though both options require similar commitment levels and lifestyle modifications. Factors such as injection frequency preferences, storage requirements, and individual response to different hormone pathways influence optimal treatment selection. Our clinical team evaluates these factors during consultation, ensuring your prescription weight loss journey aligns with realistic expectations and sustainable health outcomes.
Start Your Prescription Weight Loss Journey Today
Both Wegovy and Mounjaro are available through EverydayMeds with comprehensive clinical support from our GPhC-registered pharmacy (#9012878). New customers can begin their assessment using code FIRST40, whilst returning patients benefit from DOSE25 savings applied at checkout. Our clinical team provides ongoing monitoring and dose adjustment guidance throughout your treatment, ensuring optimal outcomes and addressing any concerns promptly. The 3-minute assessment takes the first step towards accessing prescription-only weight management solutions tailored to your individual needs. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical consultation and discover which treatment option best supports your weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
